Who Paid My Doc
Felipe Ramirez-Terrassa
Orthopaedic Surgery of the Spine New Orleans, LA Medical Doctor
NPI 1780868802 CMS profile 869376
3434 Prytania St, Suite 430, New Orleans, LA 70115
General payments
$14,755
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Felipe Ramirez-Terrassa of New Orleans, LA is reported in the CMS Open Payments database as having received $14,755 across 130 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 52nd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $201 | 4 | |
| 2024 | General | $124 | 3 | |
| 2023 | General | $6,342 | 30 | |
| 2022 | General | $4,807 | 32 | |
| 2021 | General | $411 | 13 | |
| 2020 | General | $134 | 6 | |
| 2019 | General | $2,737 | 42 |
Beside peers
- Felipe Ramirez-Terrassa
- Orthopaedic Surgery of the Spine median
- Middle half of Orthopaedic Surgery of the Spine
- National median
In program year 2025, general payments to Felipe Ramirez-Terrassa were reported at $201. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.
Show as a table
| Year | Felipe Ramirez-Terrassa | Orthopaedic Surgery of the Spine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,737 | $2,106 | $337–$18,608 | $163 |
| 2020 | $134 | $1,213 | $156–$15,082 | $114 |
| 2021 | $411 | $1,834 | $271–$15,617 | $132 |
| 2022 | $4,807 | $2,015 | $320–$17,036 | $149 |
| 2023 | $6,342 | $1,925 | $336–$14,599 | $160 |
| 2024 | $124 | $2,110 | $341–$12,483 | $164 |
| 2025 | $201 | $2,061 | $347–$14,651 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
817
Drug cost
$9,968
Branded share of claims
12%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 161 | $2,235 | |
| Tramadol Hcl | Generic | 173 | $1,704 | |
| Diclofenac Potassium | Generic | 56 | $853 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 62 | $844 | |
| Methocarbamol | Generic | 32 | $732 | |
| Tizanidine Hcl | Generic | 64 | $696 | |
| Cyclobenzaprine Hcl | Generic | 55 | $616 | |
| Diclofenac Sodium | Generic | 47 | $555 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 36 | $449 | |
| Celecoxib | Generic | 30 | $442 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 72 billing codesPaid by Medicare
$86,432
Medicare patients
212
Services billed
1,074
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Chronic kidney disease | 30% | |
| Diabetes | 28% | |
| Ischemic heart disease | 22% | |
| Depression | 22% | |
| Osteoporosis | 21% | |
| Cancer | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 12 | 16 | $90 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
130 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery of the Spine in Louisiana
Mathew Cyriac
Orthopaedic Surgery of the Spine · New Orleans, LA
Joseph Zavatsky
Orthopaedic Surgery of the Spine · Metairie, LA
Lon Baronne
Orthopaedic Surgery of the Spine · Lafayette, LA
Alexis Waguespack
Orthopaedic Surgery of the Spine · Metairie, LA
Charles Yu
Orthopaedic Surgery of the Spine · New Orleans, LA
Stephen Hoge
Orthopaedic Surgery of the Spine · Shreveport, LA
Related records
Orthopaedic Surgery of the Spine in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery of the Spine
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.